NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, has provided additional details on its Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus outbreak and other Ebola viruses in the Democratic Republic of Congo. The trial is proceeding as designed, with enrollment in Phase IIA beginning on or about Sept. 23, 2026. Phase IIA is intended to identify an optimal, well-tolerated dosing regimen and serve as a go/no-go step before Phase IIB, a randomized controlled trial designed to evaluate efficacy.
The announcement matters because it signals progress toward a treatment that could be rapidly deployed in outbreak settings where conventional intravenous therapies are difficult to administer. NV-387 is designed to attack the virus and reduce viral load, and it is delivered as an oral gummy that dissolves in the mouth without requiring water or swallowing effort. If successful, the oral treatment could be readily deployed in resource-limited settings, according to the company. NanoViricides characterized NV-387 as a broad-spectrum antiviral that mimics a host-side feature used by Ebola viruses and said there is a rationale for potential activity against Bundibugyo and other Ebola viruses.
For investors, the update offers a concrete timeline for a clinical milestone that could shape the company’s pipeline. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC. The full press release can be viewed at https://ibn.fm/zjg8X.
The broader implications extend beyond Ebola. NanoViricides is developing NV-387 as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. The company’s other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. If the oral gummy platform proves safe and effective in Ebola, it could validate a delivery method that is easier to scale and distribute than injectable antivirals, potentially accelerating responses to future outbreaks.
NanoViricides is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates and technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. Its business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses. More information is available at www.nanoviricides.com.
The update was distributed through BioMedWire, a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries, among other services. The platform also provides editorial syndication to 5,000+ outlets and social media distribution via IBN to millions of social media followers.
As with any drug development effort, there can be no assurance at this time that any of the company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. The path to typical drug development is extremely lengthy and requires substantial capital. Nevertheless, the start of Phase IIA enrollment represents a critical step in testing whether an oral antiviral can address Ebola and potentially other viral threats.
